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A reversible phospho-switch mediated by ULK1
regulates the activity of autophagy protease
ATG4B
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Upon induction of autophagy, the ubiquitin-like protein LC3 is conjugated to phosphatidy-
lethanolamine (PE) on the inner and outer membrane of autophagosomes to allow
cargo selection and autophagosome formation. LC3 undergoes two processing steps, the
proteolytic cleavage of pro-LC3 and the de-lipidation of LC3-PE from autophagosomes,
both executed by the same cysteine protease ATG4. How ATG4 activity is regulated to
co-ordinate these events is currently unknown. Here we ﬁnd that ULK1, a protein kinase
activated at the autophagosome formation site, phosphorylates human ATG4B on serine 316.
Phosphorylation at this residue results in inhibition of its catalytic activity in vitro and in vivo.
On the other hand, phosphatase PP2A-PP2R3B can remove this inhibitory phosphorylation.
We propose that the opposing activities of ULK1-mediated phosphorylation and PP2A-
mediated dephosphorylation provide a phospho-switch that regulates the cellular activity of
ATG4B to control LC3 processing.
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Autophagy is a cellular process that engulfs damagedorganelles and cytoplasmic material in double membranevesicles, which later fuse with lysosomes for degradation
and recycling of their content. Most of the ATG (autophagy-
related) genes involved in autophagy were identiﬁed in
Saccharomyces cerevisiae over a decade ago, and many of their
roles in autophagy, particularly at the early stages of autopha-
gosome formation, have been clariﬁed1. Among these is the yeast
ubiquitin-like protein Atg8 or LC3B, one of its mammalian
homologues. Upon induction of autophagy, a C-terminal glycine
of LC3B is covalently conjugated to phosphatidyl-ethanolamine
(PE) by the concerted action of ATG7, ATG3 and ATG12–5-
ATG16L2. Membrane-anchored LC3-PE has multiple functions
in autophagy. First, in S. cerevisiae, Atg8 is required for autop-
hagosome formation and its abundance regulates autophagosome
size3. Moreover, the identiﬁcation of cargo receptors that bind
through specialized domains to both LC3 and ubiquitin indicate a
role for LC3 in selective autophagy4. Finally, binding of LC3 to
FICOY suggests a role in autophagosome microtubule transport5
while binding to VPS33 links it to autophagosome–lysosome
fusion6. In addition to its regulation by conjugation, the
Atg8/LC3 family of proteins are synthesized as an inactive pro-
form with one or more amino acids shielding the C-terminal
glycine and impeding lipidation7. A cysteine protease, Atg4, is
thus needed to cleave these residues and allow exposure of the
glycine and conjugation with PE8. Interestingly, the same pro-
tease is required at a later step to de-conjugate Atg8-PE from the
outer membrane of autophagosomes probably preceding or just
after lysosome fusion, as suggested by genetic evidence in yeast9
and by immunoelectron microscopy and ﬂuorescent microscopy
in mammalian cells10, 11.
A key regulator of autophagosome formation is Atg1/ULK1,
a protein kinase that is activated early upon autophagy stimula-
tion and is needed for the recruitment of other Atg proteins to the
autophagosome formation site12. Interestingly, its kinase activity
is dispensable for the recruitment of Atg proteins but is instead
required for autophagosome formation13, 14. The ﬁnding that
ULK1 is able to bind to the downstream autophagy protein LC3,
via an LC3-interacting region, also suggests a role for Atg1/ULK1
in autophagosome formation15. Recently, the consensus sequen-
ces of surrounding residues that are phosphorylated by Atg1
have been identiﬁed16. These ﬁndings have been conﬁrmed in
mammals where a similar consensus sequence was described and
additional ULK1 phosphorylation targets in the core machinery
were identiﬁed17.
In a proteomic study to delineate the autophagy protein
network, it has been noted that ATG4B may be able to interact
directly with ULK1, together with ATG10118. Here we investi-
gated whether ULK1 was able to modulate ATG4B activity
in mammalian cells. We show that ATG4B activity is controlled
by reversible phosphorylation mediated by ULK1 and depho-
sphorylation by PP2A.
Results
ULK1 inhibits ATG4B activity and LC3B processing. First, we
investigated the effect of ULK1 expression on ATG4B activity.
Using a luciferase-based assay that monitors ATG4B-mediated
processing of LC3B2 by releasing luciferase into cellular
supernatants,19, 20 we found that overexpression of catalytic
active ULK1 reduced the amount of released luciferase and thus
of ATG4B activity when compared with a catalytically inactive
ULK1 mutant (K46I)21 when ATG4B was co-expressed in cells
(Fig. 1a). To investigate whether this was a direct effect on
ATG4B activity, we incubated recombinant active ULK1 with
ATG4B and tested the hydrolase activity in vitro towards
an LC3B-GST (glutathione S-transferase) fusion construct.
Compared with samples incubated with wild-type (WT) ATG4B,
where free LC3 quickly accumulated indicating cleavage of the
construct, in samples where ATG4B had been preincubated with
ULK1 a lower level of free LC3 accumulated, indicating decreased
ATG4B activity (Fig. 1b). In order to investigate whether the
catalytic activity of ULK1 is required for this inhibition in ATG4B
activity, we performed the LC3B-GST cleavage assay in the pre-
sence or absence of ATP. We show that cleavage of LC3B-GST is
signiﬁcantly lower in the presence of ULK1 and ATP compared
with ULK1 without ATP (Figs. 1c, d). Thus ULK1 is able to
inhibit LC3 processing by a direct effect on ATG4B, possibly by
phosphorylation of a serine residue of ATG4B.
ULK1 phosphorylates serine 316 of ATG4B. In order to identify
the target residue for ULK1-mediated phosphorylation of
ATG4B, we investigated the residues that have been found to be
phosphorylated on ATG4B in proteomic databases (www.
phosphosite.org). Strikingly, ATG4B serine 316 has been shown
to be phosphorylated in HeLa cells in vivo22 and the sequence
surrounding this residue matches the recently described ULK1
consensus motif16, 17 with an enrichment in hydrophobic amino
acids surrounding Ser316, conserved leucine/methionine residues
at position −3 and an absence of charged amino acids at positions
+1 to +3, which are instead hydrophobic (Fig. 2a). Importantly,
ATG4B serine 316 is conserved in all four ATG4 isoforms and
across eukaryotic species (Fig. 2a). To determine whether serine
316 is the target of ULK1 phosphorylation, we mutated the
residue to alanine and tested the ability of ULK1 to phosphorylate
ATG4B using in vitro phosphorylation assays. In the presence
of radio-labelled 32P-ATP, we observed an increase in 32P
incorporation in recombinant ATG4B upon incubation
with puriﬁed ULK1, indicating that ULK1 is able to directly
phosphorylate ATG4B. We found the amount of radioactivity
incorporated in ATG4B S316A mutants was strongly reduced
compared with WT ATG4B while, as a control, no difference was
observed in the amount of ULK1 auto-phosphorylation (Fig. 2b).
These results demonstrate that serine 316 is a target of ULK1
phosphorylation on ATG4B in vitro. It should be noted that an
increase in ATG4B S316A 32P incorporation was nonetheless
detected over time, suggesting that additional sites may be
phosphorylated in response to ULK1, although this effect could
also be an artifact from the in vitro phosphorylation assay.
Therefore, in order to conﬁrm that S316 is the main target for
ULK1 phosphorylation, we produced a custom phospho-speciﬁc
polyclonal antibody against ATG4B serine 316, anti-pATG4B
(Ser316). Conﬁrming our previous ﬁndings, we found that anti-
pATG4B(Ser316) strongly reacted with puriﬁed ATG4B WT after
incubation with ULK1 but not with the ATG4B S316A mutant,
attesting to the speciﬁcity of the antibody (Fig. 2c). Interestingly,
the antibody did not react with human ATG4A in the presence of
ULK1 (Supplementary Fig. 1). However, this does not rule out
that other ATG4 members are not phosphorylated by ULK1
as the phospho-antibody may not crossreact with the slightly
different motif. In fact, another study has shown that yeast
ATG4, which is strikingly different in sequence surrounding
S316 (Fig. 2a) is indeed phosphorylated by ULK1 but at a dif-
ferent residue in proximity23. Next, in order to conﬁrm whether
ULK1-mediated phosphorylation of ATG4B on Ser316 occurs
in cells, we co-transfected Halo-ATG4B with myc-ULK1 in
HEK293T cells. Compared with samples transfected with a kinase
inactive version of ULK1, the samples transfected with WT ULK1
displayed a strong increase in ATG4B Ser316 phosphorylation
(Fig. 2d). This signal was reduced in samples expressing ATG4B
S316A (Fig. 2d), as well as in protein lysates treated with
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recombinant phosphatase (Supplementary Fig. 2a), thus con-
ﬁrming that ULK1 is able to phosphorylate ATG4B on serine 316
in vivo. Finally, to conﬁrm that ATG4B is phosphorylated
on Ser316 also without ULK1 overexpression, we immuno-
precipitated tagged ATG4B from WT or ULK1/2 double knock-
out (DKO) mouse embryonic ﬁbroblasts (MEFs) treated with
okadaic acid to enhance the levels of Ser316-phosphorylated
ATG4B (see explanation below). Indeed ATG4B from ULK1/2
DKO showed a 65% reduction reduction in phosphorylation
on Ser316 (Fig. 2e), showing that endogenous ULK kinase is
responsible for phosphorylation of ATG4B on Ser316 in cells. A
residual, phosphorylation-dependent pATG4B(Ser316) antibody
signal was still observed in ULK1/2 DKO MEFs (Supplementary
Fig. 2b), suggesting that other kinases may be able to phos-
phorylate ATG4B at Ser316, albeit to a limited extent, or the
antibody might mildly crossreact with other phosphorylation sites
on ATG4B. Of interest, pATG4B(Ser316) antibody showed less
overall reactivity in lysates not overexpressing ULK1 (Supple-
mentary Fig. 2a) or in lysates from DKO MEF when compared
with their WT counterpart (Fig. 2e, Input), suggesting a possible
broader reactivity of the pATG4B(Ser316) antibody against ULK1
targets in line with the uniqueness of the ULK1 consensus
phosphorylation motif16.
ATG4B Ser316 phosphorylation reduces LC3 binding and
inhibits its catalytic activity. The region surrounding serine 316
is conserved among species beyond the ULK1 phosphorylation
motif, suggesting an important role for this region in ATG4B
structure or function. Indeed, the co-crystal structure of ATG4B
and LC324 shows that serine 316 lies at the interface between
ATG4B and LC3 and may be involved in hydrogen bonding
between ATG4B and LC3B (Fig. 3a). We hypothesized that
phosphorylation at this site might disrupt ATG4B activity by
affecting the ATG4B–LC3 complex formation, thus explaining
the observed loss of ATG4B catalytic activity upon ULK1 over-
expression. To test the effects of ULK1-mediated ATG4B phos-
phorylation towards its catalytic activity, we mutated Ser316
to aspartate to mimic the charge given by the addition of a
phosphate. First, we performed co-immunoprecipitation (IP)
experiments of LC3 with ATG4B and its mutants S316A and
S316D. We observed that both S316A and S316D showed reduced
pull-down with endogenous LC3, indicating a reduced afﬁnity for
binding (Fig. 3b, lower panel). There was also reduced binding
with overexpressed green ﬂuorescent protein (GFP)-LC3, which
was more striking for the S316A mutant compared with the
S316D mutant (Fig. 3b, upper panel). In addition, the phospho-
mimetic ATG4B S316D mutant reacted more strongly with the
anti-pATG4B(Ser316) antibody as seen by western blotting (WB),
conﬁrming the ability to mimic Ser316 ATG4B phosphorylation
(Fig. 3c). Importantly, we found that the expression of ATG4B
S316D mutant displayed little catalytic activity against LC3 in the
luciferase release assay compared with WT ATG4B (Fig. 3c). In
fact, the activity of this mutant was comparable to the catalytic
dead ATG4B C74S mutant. Notably, the ATG4B S316A mutant
also showed a lower catalytic activity, attesting to the importance
of this site but impeding the possibility of testing the effects of
the non-phosphorylatable mutant on autophagy. To conﬁrm
that these effects were direct, we produced the recombinant
phosphomimetic ATG4B S316D mutant in Escherichia coli and
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Fig. 1 ULK1 inhibits ATG4B-mediated LC3 cleavage. a Average ATG4B activity in Actin-LC3-DelN Luciferase HEK293T obtained by measuring the secreted
luciferase activity 48 h after transfection with the indicated constructs (n= 3, average± s.d.) and representative immunoblot from one experiment showing
expression of the different constructs. b GST-LC3 assay to measure in vitro activity of recombinant ATG4B after incubation with active recombinant ULK1.
Representative gel and quantiﬁcation of free cleaved LC3 (n= 3, average± s.d.). c GST-LC3 assay to measure in vitro activity of recombinant ATG4B after
incubation with active recombinant ULK1 in the presence or absence of 1 mM ATP. Representative gel showing three independent replicates for each
condition and d quantiﬁcation of free cleaved LC3 (n= 3, average± s.d.)
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tested its activity in vitro towards the LC3B-GST construct.
Compared with WT ATG4B, samples incubated with the
phospho-mimetic mutant showed little free GST accumulation,
again, almost as low as in the samples incubated with the catalytic
dead ATG4B C74S mutant (Fig. 3d). To study whether LC3-PE
de-lipidation activity was also affected by phosphorylation on
Ser316 of ATG4B, we tested the ability of the phospho-mimetic
S316D mutant to de-lipidate LC3-PE from membrane-enriched
preparations. We separated cytoplasmic and membrane fractions
of HEK293T cells treated with Torin1 (a potent mammalian
target of rapamycin (mTOR) inhibitor) and baﬁlomycin A1
(a late-stage autophagy inhbitor) and incubated the samples with
recombinant ATG4B WT, S316D and C74S mutants (Fig. 3e).
The membrane fraction showed a large amount of lipidated
LC3-II compared with the cytoplasmic fraction in treated cells,
which was sensitive to de-lipidation by WT ATG4B. Interestingly,
we found ATG4B S316D to be inactive against cleavage of
lipidated LC3, similar to catalytic inactive ATG4B C74S (Fig. 3e),
suggesting that the phospho-mimetic ATG4B S316D is inactive in
processing of LC3-II.
Phosphomimetic ATG4B S316D mutant reduces LC3 processing.
In order to assess the role of Ser316 phosphorylation on the
formation of LC3-positive autophagosomes, we used ATG4B
knockout cells generated by CRISPR/Cas9 genome editing for
rescue experiments. The haploid HAP1 cell line was modiﬁed by
CRISPR/Cas9 editing as described, resulting in a 16 nt deletion
and premature termination stop codon in exon 4 (Fig. 4a). The
absence of ATG4B in these cells was conﬁrmed by WB (Fig. 4b).
ATG4B knockout cells were then transfected with empty
Halo vector as control, Halo-ATG4B, Halo-ATG4B C74S and
Halo-ATG4B S316D and analysed for formation of LC3-positive
puncta (Fig. 4c). Staining with Halo ligand dye revealed a variable
level of construct expression (Fig. 4c). As ATG4B knockout
cells are deﬁcient in LC3 processing, we expect an absence of
LC3-positive puncta in these cells. Indeed, in ATG4B knockout
cells transfected with empty Halo-tag vector, no LC3-positive
puncta could be observed upon co-treatment with Torin1 and
baﬁlomycin A1, suggesting that ATG4B KO cells are unable to
cleave pro-LC3 (Fig. 4c and Supplementary Fig. 3). In contrast,
when WT ATG4B was expressed LC3 puncta could be observed,
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Fig. 2 ATG4B Ser316 is a target residue of ULK1 phosphorylation. a Clustal Omega multiple alignment of ATG4 protein sequences surrounding hATG4B
serine 316 from different isoforms and species; highlighted in green are serine residues and in violet hydrophobic amino acids. b In vitro radioactive
phosphorylation assay with WT or ATG4B S316A mutant at different time points after addition of recombinant active ULK1. Coomassie blue staining is
shown as an ATG4B loading control. c GST-ATG4B or GST-ATG4B S316A mutant was incubated for the indicated times with GST-ULK1 (1–283); samples
were then assayed with a custom phospho-speciﬁc antibody against Ser316 of human ATG4B—pATG4B (Ser316) or total ATG4B. d Total lysates from
wild-type (WT) or ULK1/2 double knockout (DKO) mouse embryonic ﬁbroblasts (MEFs) transfected with 3×-FLAG-tagged ATG4B or mCherry as a
control and treated with 1 µM okadaic acid for 1 h were probed with the pATG4B(Ser316) antibody and with an anti-ACTIN antibody as loading control. In
parallel, lysates from the same samples were subjected to immunoprecipitation with FLAG M2 afﬁnity gel and probed for pATG4B(Ser316) and FLAG
antibody. Phosphorylation level was calculated using densitometry, with pATG4B(Ser316) signal divided by FLAG signal for the same band, expressed as a
percentage of the WT MEF IP sample. e HEK293T lysates from samples co-transfected with mouse WT myc-ULK1 or Kinase Inactive (KI) myc-ULK1 and
the indicated Halo constructs for 24 h were blotted and probed with the indicated antibodies (one representative blot from three independent experiments)
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which were increased in number upon Torin1 and baﬁlomycin
A1 treatment, showing the recovery of ATG4B function and
the ability to activate LC3 to enable its lipidation (Fig. 4c and
Supplementary Fig. 3). Importantly, this occurred in cells that
expressed low levels of Halo-ATG4B as those expressing higher
levels showed no LC3 puncta formation likely due to excessive
LC3-ATG4B interaction impeding LC3 function, as it has been
previously observed25. Cells expressing Halo-ATG4B C74S
showed no LC3 puncta regardless of expression level, consistent
with an inability to process pro-LC3. In ATG4B knockout cells
complemented with the phospho-mimetic Halo-ATG4B S316D
mutant, LC3-positive puncta were observed showing that the
remaining activity is sufﬁcient to allow pro-LC3 cleavage. Unlike
ATG4B knockout cells expressing ATG4B WT however, in
ATG4B S316D-expressing cells even at the highest expression
levels, LC3 puncta were still observed, proving that the phospho-
mimetic mutant display defective LC3-PE de-lipidation or LC3
interaction also in vivo (Figs. 4c, d). Similarly, the S316A mutant
also showed LC3 puncta in highly expressing cells, further
supporting the notion that LC3 binding and processing is
impaired in the ATG4B mutants. In conclusion, we propose a
model whereby ATG4B activity is suppressed by ULK1-mediated
phosphorylation of Ser316. However, an ULK1-mediated
inhibition of ATG4B poses a critical question: how is ATG4B
re-activated to allow de-lipidation, which is considered to occur
distal to ULK1-positive forming autophagosomes? One possibility
is that a phosphatase exists that removes the inhibitory Ser316
phosphorylation, thus allowing for a reversible phospho-switch to
control ATG4B enzymatic activity.
PP2A is an endogenous regulator of ATG4B Ser316
dephosphorylation. To identify such phosphatase, we screened a
cDNA expression library including 74 phosphatases using
the cell-based ATG4B luciferase release assay20 (Fig. 5a and
Supplementary Data File). We identiﬁed a number of protein
phosphatases that enhanced ATG4B-mediated cleavage of LC3
when overexpressed, which were candidates for removing the
phosphate group on ATG4B Ser316 in cells. We co-expressed the
phosphatases that enhanced ATG4B-mediated LC3 processing in
the presence of Halo-ATG4B and myc-ULK1 to test their ability
to dephosphorylate ATG4B at serine 316 (Fig. 5b). Of the selected
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Fig. 3 ATG4B Ser316 phosphorylation reduces LC3 binding and inhibits its catalytic activity towards unprocessed and lipidated LC3 in vitro and in cells.
a Overview of the ATG4B-LC3 co-crystal structure from PDB 2Z0E24, zooming at ATG4B Ser316 location. LC3 is in yellow and ATG4B is in green. Red and
blue represent the oxygen and nitrogen atoms, respectively. Hydrogen bond is shown as a black dashed line. The molecular structure was generated with
PyMOL. b HeLa cells stably expressing GFP-tagged LC3B were transfected with 3×FLAG-tagged ATG4B and ATG4B mutants or mCherry as control and
subjected to immunoprecipitation with FLAG M2 afﬁnity gel. The blots were probed for interaction of the 3×FLAG-tagged proteins with GFP-LC3B using
GFP antibody (upper panel) and endogenous LC3B with LC3B antibody (lower panel), and 3×FLAG-ATG4B was detected using FLAG antibody (middle panel).
c ATG4B activity was measured in the Actin-LC3-DelN reporter cell line 48 h after transfection with the WT, catalytic inactive (C74S), phosphomimetic
(S316D) and non-phosphorylatable (S316A) Halo-ATG4B constructs (n= 3, average± s.d., and representative blot showing the correct expression of the
constructs). Values displayed are the relative intensity of phosphorylated ATG4B Ser316 normalized to Halo-ATG4B, relative to WT HaloATG4B
expression (unpaired two-sided t-test). d Puriﬁed recombinant WT, phosphomimetic (S316D) and catalytic inactive (C74S) GST-ATG4B (0.004mgmL−1)
were tested in vitro for their ability to cleave LC3B-GST (1 mgmL−1). e Cytoplasmic and non-nuclear membrane fraction preparations from HEK293T cells
treated with 250 nM Torin and 10 nM baﬁlomycin A1 for 3 h were incubated with the indicated GST-ATG4B WT, S316D and C74S mutants for 30min at
37 °C, blotted and probed with the indicated antibodies. LAMP1 and PRDX1 were used as loading controls for the membrane and cytoplasmic fractions,
respectively, and GST-ATG4B was detected using anti-ATG4B (one representative blot is shown)
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phosphatases PPM1A, PPM1F and the regulatory subunit 3B of
PP2A were found to decrease the phosphorylation status of
ATG4B on serine 316 (Fig. 5b). Consistent with this
ﬁnding, inhibition of PP2A with okadaic acid in cells stably
expressing Halo-ATG4B, resulted in a strong increase of ATG4B
Ser316 phosphorylation, showing that PP2A is endogenously
involved in the dephosphorylation of ATG4B on this residue
(Fig. 5c). How the activity of this phosphatase is controlled
during autophagosome initiation and formation requires further
investigation.
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Fig. 4 Quantiﬁcation of LC3-positive autophagosomes in ATG4B knockout cells rescued with the phosphomimetic ATG4B S316D mutant. a Validation of
CRISPR-mediated modiﬁcation to the genomic locus of ATG4B exon 4 in the HAP1 ATG4B KO cell line. The gene structure of the WT human ATG4B locus
on chromosome 2 is shown, and the region in exon 4 targeted for modiﬁcation is revealed at the sequence level. The DNA sequence targeted by the
custom sgRNA is shown in bold. The 16 bp deletion in the ATG4B KO clone results in a frameshift and early stop codon, as shown by the DNA sequence
alignment. b Protein-level validation of ATG4B knockout. Lysates from untreated HAP1 control and ATG4B KO cells were run on a 4–20% polyacrylamide
gel and immunoblotted with antibodies against ATG4B and beta-actin. The ATG4B KO cells showed a total absence of the speciﬁc band representing
ATG4B. c ATG4B KO HAP1 cells were transfected with the indicated Halo constructs. After 24 h, cells were simultaneously stained live with a Halo ligand
dye and treated with 250 nM Torin1 and 10 nM baﬁlomycin A1 for 3 h, prior to ﬁxation and staining for endogenous LC3. Arrowheads indicate high Halo
construct-expressing cells, and arrows indicate cells expressing low levels of these constructs. Scale bar 10 µm. d Quantiﬁcation of the average number of
autophagosome per cell in the high expressing cells is shown (Tukey’s plot, n= 10 ﬁelds, with an average of 5 quantiﬁed cells per ﬁeld). ****p< 0.0001,
NS not signiﬁcant (Sidak’s multiple comparison test)
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Discussion
In summary, we have discovered that ULK1 inhibits LC3
processing through direct phosphorylation and inhibition of
ATG4B. We have identiﬁed the target residue as Ser316, which
lies at the interaction interface with LC3B and we propose that
LC3 co-ordination is impaired through the bulky negative
charged phospho-serine residue. We propose that LC3 processing
is controlled by a reversible phospho-switch to inhibit and re-
activate the catalytic activity of ATG4B, mediated by ULK1/2 and
the opposing phosphatase. In fact, we have identiﬁed PP2A as a
phosphatase able to dephosphorylate ATG4B on serine 316.
PP2A is a family of >200 biochemically distinct heterotrimeric
complexes composed of a combination of one catalytic domain,
one scaffold subunit and one of many possible regulatory
subunits26. The PP2A inhibitors okadaic acid and rifampicin
have been shown to block starvation-induced autophagy27–29
and speciﬁc PP2A-regulatory subunits have been linked to the
regulation of autophagy by acting upstream on mTOR signalling.
Our identiﬁcation of PP2R3B-containing PP2A complexes in the
regulation of ATG4B provides an mTOR-indepenent molecular
explanation for the described role of PP2A in autophagosome
expansion observed in Drosophila and mammalian cells30, 31.
However, the regulation of PP2A activity during autophagosome
formation is complex and complicated by the fact that loss of
PP2A activity modulates early steps in autophagosome formation.
For instance, PP2A activity is required for dephosphorylation of
ULK1 and activation of the ULK1 kinase29. Thus an inhibition
of PP2A activity translates into a block of autophagy that is
correlated with a reduction in ULK1 phosphorylation targets.
Further studies are needed to distinguish between speciﬁc subsets
of PP2A and their role in early and late steps in autophagy.
Although we do not demonstrate ULK1-dependent phos-
phorylation of endogenous ATG4B, we propose that cycles of
phosphorylation and dephosphorylation of ATG4B regulate the
activity of ATG4B and LC3 processing. Indeed, endogenous
phosphorylation of S316 has been demonstrated in another
study22, thus supporting our ﬁndings. How this regulatory
phospho-switch is controlled within the spatio-temporal context
of autophagy is presently unclear. As ULK1 is mainly localized to
the forming autophagosome upon induction of autophagy, it is
possible that localized activation of ULK1 at the autophagosome
formation site results in the phosphorylation of ATG4B on serine
316, thus protecting nascent autophagosomes from premature
LC3 de-lipidation and, in concert with the conjugation machin-
ery, increasing overall LC3-II availability. At the same time,
inhibition of ATG4B-mediated de-lipidation at the immature
autophagosomes ensures that LC3 coating is maintained through
early steps in autophagosome formation. Over time, ULK1
may dissociate from autophagosomes or alternatively become
inactivated by a yet unknown mechanism, thus releasing the
inhibitory phosphorylation of ATG4B during later stages of
autophagy. In addition, the presence of highly abundant PP2A
might ensure dephosphorylation of ATG4B at sites of low ULK1
activity, thus allowing ATG4B to process pro-LC3 and potentially
to de-lipidate incorrectly lipidated LC3–PE that can occur on
non-autophagosome membranes32. It remains to be assessed
whether the negative regulation exterted by oxidation on ATG4B
activity33 acts in concert or independently of ULK1 regulation.
This could be aided by addditional post-translational modiﬁca-
tions such as phosphorylation at Ser383 and Ser392 by as yet
unidentiﬁed kinase or kinases that activates LC3 de-lipidation34.
These studies pave the way to the understanding of how
autophagy genes are regulated by post-translational mechanisms
in order to allow the co-ordination of autophagosome formation
and lysosomal delivery.
Methods
Plasmids. Halo-ATG4B expression plasmid (pHTNATG4B) was created by
sub-cloning full-length ATG4B from pEAK-ATG4B with EcoRI and NotI into
pHTN-Halotag CMV-neo plasmid (Promega). Mutant S316D was generated
by PCR using Ser316 forward (5′-GACCCGGACATCGCTGTGGG-3′) and reverse
(5′-CCCACAGCGATGTCCGGGTC-3′) primers, C74S with forward (5′-GCTGG
GGCAGCATGCTGC-3′) and reverse (5′-GCAGCATGCTGCCCCAGC-3′)
primers and S316A with forward (5′-GACCCGGCCATCGCTGTGGG-3′) and
reverse (5′-CCCACAGCGATGGCCGGGTC-3′) primers. pGEXATG4B was
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Fig. 5 A phosphatase screen identiﬁes PP2A as an endogenous regulator of ATG4B Ser316 dephosphorylation. a Schematic workﬂow of the cDNA
phosphatase screen. b HEK293T cells after 24 h co-transfection with selected phosphatases and myc-ULK1 and Halo-ATG4B were analysed for the
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created by sub-cloning ATG4B from pEAK-ATG4B with EcoRI and NotI into
the bacterial expression vector pGEX6P-1 (GE Healthcare, 27-4597-01).
pGEXATG4BC74S was created by PCR using pGEXATG4B as a template and
primers C74S forward (5′-CCATGCTGCGGTGTGGACAGATG-3′) and C74S
reverse (5′-AGCCCCAGCCTGTGTCCGAGGT-3′), pGEXATG4BS316A was
created by PCR using pGEXATG4B as a template and primers S316A forward
(5′-GCCATCGCTGTGGGGTTTTTCTGT-3′) and S316A reverse (5′-CGGGTCA
AGCTCCGCGATGCTCAT-3′), pGEXATG4BS316D created by sub-cloning
ATG4B S316D from pHTNATG4BS316D with EcoRI and NotI into the bacterial
expression vector pGEX6P-1. pGEX GST-ULK1cd, encoding ULK1 catalytic
domain (ULK1cd, amino acids 1–283), was obtained by PCR using full-length
human ULK1 as a template and EcoRI-ULK1cd forward (5′-AAAGAATTCATG
GAGCCCGGCCGCGGCGGCACAG-3′) and ULK1cd-stopNotI reverse (5′-GCG
GCCGCTTACGAGGGGCTGGCATCGAGGAAAGG-3′) primers and cloned into
the bacterial expression vector pGEX6P-1 using EcoRI and NotI. pETLC3-GST was
created by PCR amplifying LC3B2 from the Actin-LC3-DelN reporter with LC3
forward (5′-ATGCCGTCGGAGAAGACCTTCAAG-3′) and reverse (5′-CACTGA
CAATTTCATCCCGAACGT-3′) primers and amplifying GST from pGEX6P-1
with GST forward (5′-ATGTCCCCTATACTAGGTTATTGG-3′) and GST-Hin-
dIII reverse (5′-TTTAAGCTTAGGTTTTCACCGTCATCACCGAAA-3′) primers
and the resulting fragments were cloned in pET21d (Novagen, 69743-3) previously
digested with NcoI, blunted by Klenow large fragment DNA polymerase and
HindIII. All PCR were performed at 30 cycles using either Pyrobest DNA
polymerase (Takara, R005A) (For pGEXATG4BC74S, pGEXATG4BS316A, pGEX
GST-ULK1cd and pET LC3-GST) or Phusion polymerase (New England Biolabs,
M0530S). pDONR223 ATG4B was created by recombining ATG4B ampliﬁed by
PCR from pHTN-HaloTag-ATG4B with pDONR223 and transforming in
DH5alpha and selecting on Ampicillin/Spectinomycin plates. A lentiviral vector for
the expression of N-terminally Halo tagged proteins was created by cloning
HaloTag from pHTN-HaloTag vector in the EcoRV and NheI sites of the lentiviral
pLD-Gateway-Puro-NVF (gift of Julia Petschnigg) and used to create the gateway
compatible N-terminal HaloTag-ATG4B vector with a Neomycin mammalian
selection cassette. 3×FLAG-tagged ATG4B mutant expression vectors were
generated by gateway recombination of ATG4B entry clones with pCMV-
tripleFLAG-Gateway35. Mouse Myc-ULK1 and Myc-ULK1 kinase inactive K46I
mutant plasmids were a kind gift from Sharon Tooze, and myc-hULK1 was a gift
from Do-Hyung Kim (Addgene plasmid no. 31961)36.
Chemical probes. Chemical probes’ stock solutions were made in dimethyl
sulphoxide at a concentration of 10 µM baﬁlomycin (Sigma, B1793), 250 µM
Torin1 (Merck-Millipore, 475991) and 1 mM okadaic acid (Cell Signaling, 5934S).
Halo ligand dye used was HaloTag TMRDirect Ligand (Promega, G2991) and
added to the culture medium of live cells at a ﬁnal concentration of 0.1 µM for the
same duration as compound treatment.
Antibodies. A rabbit polyclonal phospho-serine 316 ATG4B antibody was custom
produced by GeneScript by rabbit immunization. pATG4B(Ser316) was diluted
1:1000 in PBST (PBS 0.005% Tween-20) 3% bovine serum albumin (BSA,
Sigma-Aldrich, A7906).
Commercially available antibodies and dilutions used are s follows: rabbit
ATG4B antibody (Cell Signaling, 5299S, WB dilution 1:1000); mouse monoclonal
antibody Anti-HaloTag (Promega, G9211, WB dilution 1:1000); rabbit anti-LC3B
antibody (Sigma-Aldrich, L7543, WB dilution 1:1000, immunoﬂuorescence
dilution 1:400); rabbit anti-Peroxiredoxin 1 antibody (ABfrontier, LF-MA0031,
1:1000); mouse anti-β-actin (Sigma A1978, WB dilution 1:2000); mouse anti Myc
(Millipore, CB430, WB dilution 1:400); rabbit anti-Vinculin (Abcam, AB129002,
WB dilution 1:10000); mouse anti-LAMP1 (BD Biosciences, 611042, WB dilution
1:500); mouse anti-GFP (Clontech, 632381, WB dilution 1:1000); mouse
biotinylated anti-FLAG (Sigma-Aldrich, F9291, WB dilution 1:1000); and goat
anti-GST (GE Healthcare, 27-4577-01, WB dilution 1:1000).
Protein puriﬁcation. Expression plasmids pGEXATG4B, pGEXATG4BC74S,
pGEXATG4BS316A, pGEXATG4BS316D, pGEXULK1cd and pETLC3B-GST
were transformed into E. coli BL21 (DE3)-R3-lambda-PPase obtained from the
Structural Genomics Consortium, Oxford University, Oxford, UK. The proteins
were induced by 0.1 mM isopropyl-D-1-thiogalactopyronoside at 18 °C overnight.
GST-tagged proteins were puriﬁed using Glutathione Sepharose 4B (GE Health-
care, 17-0756-01) as described previously37. The proteins were further puriﬁed and
concentrated using Amicon ultra centrifulgal ﬁlter units ultra-15, molecular weight
cutoff (MWCO) 30 kDa (Sigma-Aldrich, Z717185-8EA) or MWCO 10 kDa
(Sigma-Aldrich, Z706345-8EA). PreScission Protease (GE Healthcare, 27-0843-01)
was used for digestion when necessary to remove GST from GST-tag proteins. The
following recombinant proteins were commercially obtained: GST-tagged ULK1
(Sigma, SRP5096) and GST-tagged ATG4A (Abnova, H00115201-P01). All
recombinant proteins were stored at −80 °C in 50 mM Tris-HCl, pH 8.0, 150 mM
NaCl, 0.5 mM EDTA, 0.1 mM EGTA, 33% glycerol and 1 mM dithiothreitol
(DTT). Sequence alignment was performed with Clustal Omega38 at www.uniprot.
org. Protein structure visualizations were generated with PyMOL Molecular Gra-
phics System (DeLano Scientiﬁc, Palo Alto, CA, USA).
In vitro phosphorylation assays. In vitro radioactive assays were performed by
incubating 100 ng recombinant ATG4B diluted in assay buffer (20 mM Tris-HCl
pH 7.5, 10 mM MgCl2, 5 mM DTT, 20 µM cold ATP and 0.16 µM ATP [γ-32P]
PerkinElmer NEG502A100UC) in the presence of 10 ng recombinant ULK1
(catalytic domain) or 3 µL of active recombinant ULK1 (Sigma-Aldrich, SRP5096)
at 30 °C for the indicated times. The reaction was stopped by adding 5× sample
buffer (250 mM Tris-Cl pH 6.8, 10% sodium dodecyl sulphate (SDS), 50% glycerol,
25% β-mercaptoethanol or 0.5 M DTT and 0.05% bromophenol blue) and boiling
for 5 min. Samples were loaded on NUPAGE Acrylamide gel (Invitrogen,
NP0321BOX). Gels were stained with InstantBlue Protein Stain (Expedeon, ISB1L)
before drying on ﬁlter paper and measuring incorporated radioactivity by exposing
on photographic ﬁlm (Bio-Rad).
LC3-GST assay. LC3-GST was diluted at 1 mgmL−1 in assay buffer (50 mM
Tris-HCl pH 8.0, 150 mM NaCl, 5 mM DTT), and after addition of ATG4B
(0.005 mg mL−1), samples were incubated at 37 °C and the reaction was stopped by
adding 5× sample buffer and boiling for 5 min. For testing the effects of ULK1 on
ATG4B activity, the LC3-GST assay was performed in the Kinase Buffer as
described. For testing the dependency of the reaction to ATP, 2 µg of recombinant
WT ATG4B or ATG4B C74S was incubated with 0.02 µg ULK1 in the presence or
absence of 1 mM ATP for 30 min at 37 °C. ATG4B and the C74S mutant were then
diluted 500× and incubated with LC3-GST and incubated for 60 at 37 °C. Samples
were loaded on Mini-PROTEAN TGX Precast Gels (Bio-Rad) and run on Bio-Rad
mini-protean tetra electrophoresis system (Bio-Rad). Gels were stained in
InstantBlue Protein Stain (Expedeon, ISB1L) and imaged on a LiCor Odyssey
ﬂuorescence scanner at a wavelength of 700 nm. Images were quantiﬁed in Fiji39
(http://ﬁji.sc/Fiji) using the analyse>gel built-in function.
LC3-PE enrichment. HEK-293T cells were collected and washed in PBS. Cells were
then homogenized in Resuspension Buffer (Hepes-KOH pH 7.5, 0.22 M Mannitol,
0.07 M Sucrose and protease inhibitors) by passing the sample 10 times through a
27 G needle. Nuclei were discarded by centrifugation at 300×g for 10 min, and the
cytosolic and membrane fraction were separated by centrifugation at 7000 g for 10
min. The membrane pellet was resuspended in the same volume of resuspension
buffer and 0.5% Triton X100 and 5 mM DTT were added to each fraction.
Recombinant ATG4B was then added at a concentration of 0.004 mgmL−1 and
incubated at 37 °C for 20 min, after which 5× sample buffer was added and samples
were boiled at 95 °C for 5 min and assessed by WB.
Cell lines culture and transfection. MEF cells and short tandem repeat
(STR)-proﬁled HeLa (ATCC_CCL2) and HEK293T (ATCC_CRL-3216) cells were
cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM; Life Technologies,
61965) supplemented with 10% foetal bovine serum (FBS; Life Technologies,
10500), 10 UmL−1 Penicillin and 0.1 mgmL−1 Streptomycin (Sigma-Aldrich,
P0781) and 1 mM Pyruvate (Life Technologies, 11360) at 37 °C 5% CO2.
HAP1 cells were cultured in Iscove’s Modiﬁed Dulbecco’s Medium (IMDM; Life
Technologies, 21980-065) supplemented with 10% FBS and antibiotics at 37 °C 5%
CO2. HAP1 ATG4B knockout cells were generated by and obtained from Horizon
Genomics (HZGHC001241c011). ULK1/2 DKO MEFs were obtained from Sharon
Tooze.
MEF, HEK293T and HeLa cells were transfected with PEI “Max”, MW 40,000
(Polyscience, 24765-2). PEI was added at a ratio of DNA (µg):PEI (µg) of 1:4 to
DNA diluted in DMEM without serum and antibiotics, brieﬂy vortexed and added
to cells growing in complete medium after a 20 min incubation. After 4–16 h,
the medium was replaced with fresh medium. HAP1 cells were transfected with
X-tremeGENE HP (Roche, 06366244001) at a 1:1 ratio with 500 ng of DNA in
24-well plates, changing medium after 4 h.
Lentiviral packaging and transduction. Halo was cloned in a lentiviral Gateway
destination vector, under the control of a CMV promoter and harbouring a
mammalian Neomycin selection cassette. HEK293T cells were grown in complete
DMEM in a six-well plate and co-transfected with 900 ng psPAX2 (packaging
plasmid, Addgene no. 12260), 100 ng pMD2.G (envelope plasmid, Addgene no.
12259) and 1 µg of Halo-ATG4B lentiviral plasmid per well using 2 µL
X-tremeGENE per µg of DNA. At 18 h post-transfection, medium was replaced
with complete IMDM. Viral supernatant was harvested at 72 h post-transfection,
0.22 µm ﬁltered and frozen at −80 °C. HeLa cells were seeded in 24-well plates and
infected overnight with 300 µL of viral supernatant containing 8 µg µL−1 polybrene.
Cells were selected 48 h postinfection for 1 week in the presence of 400 µg mL−1
G418 (Sigma-Aldrich, no. G8168).
ATG4B activity cell assay. STR-proﬁled HEK293T cells stably expressing the
Actin-LC3-DelN reporter were seeded in 96 multiwell plates at 20,000 cells
per well. A total of 250 ng of DNA were transfected by mixing with 0.7 µL of
Lipofectamine 2000 (Life Technologies, 11668-019) in a 50 µL total volume of
OPTIMEM (Life Technologies, 31985), incubating 20 min at room temperature
(RT) and then adding to the wells. After 48 h, 10 µL of supernatant were transferred
to a new plate (Greiner Bio-One, 655076) and 90 µL of 10 µg mL−1 native
coelenterazine (Insight Biotechnology, sc-205904, stock 1 mgmL−1 in MeOH/1%
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HCl) diluted in 0.5 M Tris-HCl pH 7.4 was added prior to measuring luminescence
in a PerkinElmer Envision II plate reader.
Immunocytochemistry and confocal microscopy. HAP1 ATG4B knockout cells
were grown on glass coverslips, ﬁxed with 4% paraformaldehyde for 15 min RT,
washed twice in PBS, ﬁxed in ice-cold MeOH for 15 min at −20 °C, washed twice in
PBS and quenched 20 min at RT in 50 mM NH4Cl. After permeabilization with
0.1% TX-100, samples were blocked in PBS 3% goat serum for 60 min. Primary and
secondary antibodies were diluted in blocking solution and incubated for 60 min
each at RT. Nuclei were stained with 1 µg mL−1 Hoechst 33342 in PBS for 10 min.
Coverslips were mounted with ProLong Diamond Antifade Mountant (Thermo-
Fisher, P36970) and sealed with nail polish before imaging. Slides were imaged
using a Leica TCS SP5 confocal laser scanning microscope (×63 oil immersion
objective, NA= 1.4) with sequential channel acquisition. For discrimination of
Halo-ATG4B expression, non-saturated images were used for quantiﬁcation.
Image quantiﬁcation. Confocal images were imported in Columbus 2.4 with
Omero 4.4.7 (PerkinElmer). Imported images were then batch analysed with
Acapella 3.1, with the following script: ﬁnd nuclei in DAPI channel (method B),
ﬁnd cytoplasm in LC3 channel (method A), ﬁnd spots in LC3 channel (method B,
>6px2), divide cells according to Halo mean cytoplasmic pixel intensity in high
(>180), medium (>25, <180) and low (<25) and calculate the average number of
LC3 spots in each class.
Western blotting. Cells were collected and washed once in PBS. Cells were then
lysed in 1% NP-40 lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40)
supplemented with protease inhibitors (Complete EDTA-Free, Roche, cat
04693132001) and phosphatase inhibitors (PhosSTOP, Roche, cat 04906845001)
for 15 min on ice and the insoluble material was discarded after 15 min cen-
trifugation at 4 °C, 5× sample buffer was then added to the supernatant, boiled for
5 min and loaded on gels with PageRuler Plus Prestained (ThermoFisher, 26619) as
protein ladder. For all WB, 4–20% or 7.5% precast Bio-Rad gels were used on a
Bio-Rad mini-PROTEAN system and blotted on nitrocellulose 0.45 µm (Bio-Rad,
162-0115) or Immobilon-FL 0.45 µm polyvinylidene diﬂuoride membrane
(Merck-Millipore, IPFL00010) following the manufacturers’ instructions.
Membranes were blocked in PBS-T (PBS 0.005% Tween-20) 5% Milk (Sigma,
70166-500G) or TBS-T 3% BSA for phospho-specﬁc antibodies. Primary antibodies
were diluted in blocking buffer and incubated for either 1 h at RT or 4 °C overnight.
Secondary antibodies were goat anti-rabbit immunoglobulin G (IgG) (H+L)
IRDye800 (LiCor, 926-32211) in PBS-T supplemented with 5% milk or TBS-T
supplemented with 3% BSA and goat anti-mouse IgG (H+L) IRDye680 LT
(LI-COR, 926-68020) in PBS-T supplemented with 0.02% SDS and 5% milk.
Detection was performed on ImageQuant chemilumenscent imaging system
(GE Healthcare) or Odyssey infrared imaging system (LiCor). For stripping
antibodies from membranes, Restore PLUS Western Blot Stripping Buffer
(ThermoScientiﬁc, 46430) was used following the manufacturer’s instructions.
Densitometry was performed as described for LC3-GST assay. Uncropped scans of
the blots are provided in Supplementary Fig. 4.
IP experiments. HeLa cells stably expressing GFP-LC3B grown in 10 cm tissue
culture dishes were transfected with cDNA expression constructs using PEI (a total
of 10 µg DNA mixed with 40 µg PEI per dish). After 24 h, cells were washed in PBS
and lysed in 600 µL of IP buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1 mM
EDTA, 1% Triton X-100 and protease inhibitors) and samples were cleared by
centrifugation at 15, 000×g for 10 min at 4 °C. After 50 µL input sample was
collected into a separate tube and boiled in sample buffer, the remaining cleared
sample was loaded onto ANTI-FLAG M2 Afﬁnity Gel (Sigma, A2220) that had
previously been prepared by washing three times with 1 mL IP buffer. Approxi-
mately 30 µL of packed gel was used per sample, and binding was performed at 4 °C
for 3 h on a tube rotator. Gel was washed three times with 1 mL IP buffer and
bound protein was eluted from the gel by boiling in 60 µL sample buffer for 5 min
at 95 °C. WB was performed as described and GFP was speciﬁcally detected with
anti-GFP antibody and revealed using horseradish peroxidase (HRP)-conjugated
protein A (Abcam, ab7456) to avoid detection of denatured mouse FLAG M2
antibody chains. 3×FLAG-ATG4B was subsequently speciﬁcally detected using
biotinylated anti-ﬂag antibody and revealed with streptavidin-conjugated
IRDye680LT (LiCor, 926-68031) to avoid detection of mouse anti-GFP.
Endogenous LC3B was speciﬁcally detected on a cut portion of the same
membrane using goat anti-rabbit HRP (Santa Cruz, sc-2004).
For IP of 3×FLAG-ATG4B in WT and ULK1/2 DKO MEFs, a similar procedure
was performed with modiﬁcations. At 48 h post-transfection, cells were treated
for 1 h with 1 µM okadaic acid, washed in PBS and lysed in 1 mL MEF IP buffer
(as above, but supplemented with phosSTOP and without EDTA). Following
column binding and washing (once in MEF IP buffer and twice in MEF IP buffer
lacking phosSTOP), competitive elution was performed in 120 µL MEF IP buffer
lacking phosSTOP and containing 3×FLAG peptide (Sigma, F4799) at a
concentration of 100 µg mL−1. WB was performed and the entire membrane was
ﬁrst probed with pATG4B (Ser316). Following this, total 3×FLAG-ATG4B was
detected using streptavidin-conjugated ﬂuorescent secondary antibody as above,
and actin was detected using IRDye800CW goat anti-mouse secondary antibody
(LiCor, 925-32210).
Phosphatase treatment of cell extracts. Cell lysates or IP samples were divided
equally into tubes on ice containing 1/10 volume of Calf Intestinal Phosphatase
(New England BioLabs, M0290L) or an equivalent volume of lysis buffer or IP
buffer for control reactions. Tubes were incubated at 37 °C for the times indicated,
and the reaction was stopped by addition of 5× sample buffer with immediate
boiling at 95 °C. Samples were then subjected to WB analysis.
Phosphatase cDNA expression screen. HEK293T cells were transiently
co-transfected with Actin-LC3-DelN and an arrayed cDNA expression library
(OpenBiosystems, MHS5004_PhosFLcDNA_CMV) in triplicates. In each well of a
96-well plate, 30,000 cells were seeded and transfected the following day with 100
ng of the Actin-LC3-DelN reporter and 100 ng of each cDNA expression clone
using Lipofectamine 2000. Supernatants were removed from cells after 24 h and
assayed for luciferase activity as described previously40: 10 µL of supernatant were
transferred to a new plate (Greiner Bio-One, 655076) and 90 µL of the 10 µg mL−1
native coelenterazine (Insight Biotechnology, sc-205904, stock 1 mgmL−1 in
MeOH/1%HCl) diluted in 0.5 M Tris-HCl pH 7.4 was added prior to measuring
luminescence in a PerkinElmer Envision II plate reader.
Statistical analysis. Indicated p-values were calculated using an unpaired
two-tailed t-test in Microsoft Excel. Histograms show means and error bars
represent s.d. Box plot in Fig. 4d was generated using the Tukey’s method in Prism
7 (GraphPad) and p-values in this chart were calculated using ordinary one-way
analysis of variance with Sidak’s multiple comparisons test.
Data availability. All relevant data from this article are available from the authors.
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